NCAM1 and COVID-19: The results showed that there were significant differences in the levels of IL-2, IL-10, absolute count of lymphocyte subsets (CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, and CD19+ B cells), CD16+CD56+ NK cells, and neutrophils between patents with COVID-19 and cancers.